Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharma (CPRX)
NASDAQ:CPRX
CPRX Stock Chart & Stats
$23.74
-$0.35(-1.79%)
At close: 4:00 PM EST
$23.74
-$0.35(-1.79%)
Day’s Range― - ―
52-Week Range$19.05 - $26.58
Previous CloseN/A
Volume328.11K
Average Volume (3M)1.32M
Market Cap
$2.92B
Enterprise Value$1.82B
Total Cash (Recent Filing)$689.89M
Total Debt (Recent Filing)$2.89M
Price to Earnings (P/E)13.9
Beta0.72
Next Earnings
Mar 18, 2026EPS Estimate
0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.42
Shares Outstanding122,912,384
10 Day Avg. Volume1,654,370
30 Day Avg. Volume1,322,059
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)3.40
Price to Sales (P/S)5.03
P/FCF Ratio10.33
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue3.14
Enterprise Value/Gross Profit3.76
Enterprise Value/Ebitda5.97
Forecast
1Y Price Target
$34.00Price Target Upside43.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.55
Revenue Forecast (FY)$575.01M
Bulls Say, Bears Say
Bulls Say
Market EducationCPRX is focused on educating oncology centers on updated care pathways, which is anticipated to accelerate the identification and transition of new patients to Firdapse.
Product GrowthCancer-associated LEMS is expected to be a key driver for the next phase of growth for Firdapse, highlighting significant unmet need and opportunity for expansion.
Product Launch SuccessThe strength of the Agamree launch continues to exceed expectations, with significant revenue and broad adoption across legacy corticosteroid segments.
Bears Say
Revenue ErosionMultiple generics entering the market are expected to result in more impactful erosion of Fycompa revenue, affecting performance in future periods.
Catalyst Pharma News
CPRX FAQ
What was Catalyst Pharma’s price range in the past 12 months?
Catalyst Pharma lowest stock price was $19.05 and its highest was $26.58 in the past 12 months.
What is Catalyst Pharma’s market cap?
Catalyst Pharma’s market cap is $2.92B.
When is Catalyst Pharma’s upcoming earnings report date?
Catalyst Pharma’s upcoming earnings report date is Mar 18, 2026 which is in 85 days.
How were Catalyst Pharma’s earnings last quarter?
Catalyst Pharma released its earnings results on Nov 05, 2025. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.332 by $0.088.
Is Catalyst Pharma overvalued?
According to Wall Street analysts Catalyst Pharma’s price is currently Undervalued.
Does Catalyst Pharma pay dividends?
Catalyst Pharma does not currently pay dividends.
What is Catalyst Pharma’s EPS estimate?
Catalyst Pharma’s EPS estimate is 0.31.
How many shares outstanding does Catalyst Pharma have?
Catalyst Pharma has 122,912,384 shares outstanding.
What happened to Catalyst Pharma’s price movement after its last earnings report?
Catalyst Pharma reported an EPS of $0.42 in its last earnings report, beating expectations of $0.332. Following the earnings report the stock price went down -1.824%.
Which hedge fund is a major shareholder of Catalyst Pharma?
Currently, no hedge funds are holding shares in CPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Catalyst Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.00 (43.22% Upside)
$34.00 (43.22% Upside)
Blogger Sentiment
Bullish
CPRX Sentiment 66%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $878.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.62%
12-Months-Change
Fundamentals
Return on Equity
27.52%
Trailing 12-Months
Asset Growth
36.22%
Trailing 12-Months
Company Description
Catalyst Pharma
Catalyst Pharmaceuticals, Inc. (CPRX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for rare neurological diseases. The company primarily operates in the pharmaceutical sector, specializing in the treatment of conditions such as Lambert-Eaton Myasthenic Syndrome (LEMS) and congenital myasthenic syndromes. Catalyst's flagship product is Firdapse (amifampridine), which is approved for the treatment of LEMS in adults and has been pivotal in addressing unmet medical needs in this niche market.
CPRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Catalyst Pharmaceuticals' strong financial performance, driven by significant growth in FIRDAPSE and AGAMREE, as well as the company's solid cash position and raised revenue guidance. However, the decline in FYCOMPA revenue due to generic competition and ongoing patent litigation for FIRDAPSE were noted challenges.View all CPRX earnings summariesCPRX Stock 12 Month Forecast
Average Price Target
$34.00
▲(43.22% Upside)
Technical Analysis
Amicus
―
Travere Therapeutics
―
Ocular Therapeutix
―
ImmunityBio
―
Liquidia Technologies
―
Ownership Overview
6.08% Insiders
17.66% Mutual Funds
19.56% Other Institutional Investors
30.74% Public Companies and Individual Investors